Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Chinese

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2026, Vol. 31 ›› Issue (10): 1377-1384.doi: 10.12092/j.issn.1009-2501.2026.10.008

Previous Articles    

Predicting dual response failure to semaglutide in obese type 2 diabetes: development and validation of a visual scoring system

Fandong MENG(), Jingjing FAN, Xin LIU, Lulu KONG()   

  1. Department of Endocrinology, Affiliated Hospital of Xuzhou Medical University, Xuzhou 221000, Jiangsu, China
  • Received:2025-09-01 Revised:2025-10-27 Online:2026-10-26 Published:2026-11-11
  • Contact: Lulu KONG E-mail:504102802@qq.com;lulu-kong@163.com

Abstract:

AIM: To develop and validate a nomogram-based scoring system for predicting the risk of failing to achieve dual response in glycemic control and weight loss with semaglutide in obese type 2 diabetes mellitus (T2DM) patients. METHODS: A total of 347 obese T2DM patients who received subcutaneous semaglutide injection therapy for the first time at our endocrinology department between January 2023 and January 2025 were enrolled. Based on the treatment timeline, patients recruited from January 2023 to June 2024 were assigned to the training set (n=243), while those recruited from July 2024 to January 2025 were assigned to the validation set (n=104). According to dual response status, patients in the training set were further divided into a response group (n=159) and a non-response group (n=84). Univariate and multivariate logistic regression analyses were employed to identify risk factors for failing to achieve the dual response, and a nomogram prediction model was constructed based on these factors. RESULTS: Lower BMI (OR: 0.533, 95%CI: 0.381-0.748), longer duration of diabetes (OR: 1.591, 95%CI: 1.294-1.957), lower FBG (OR: 0.349, 95%CI: 0.238-0.511), lower HbA1c (OR: 0.380, 95%CI: 0.241-0.599), and lower visceral fat content (OR: 0.989, 95%CI: 0.981-0.997) were identified as independent risk factors for failing to achieve the dual response (all P<0.05). Model validation demonstrated good performance: Hosmer-Lemeshow test results for the training and validation sets were (χ2=12.463, P=0.132) and (χ2=7.753, P=0.445), respectively, indicating good calibration, which was further supported by calibration curves closely aligning with the ideal line. The areas under the ROC curve (AUC) were 0.956 (95%CI: 0.940-0.971) for the training set and 0.814 (95%CI: 0.790-0.838) for the validation set. Decision curve analysis showed positive net benefits across a threshold probability range of 0% to 100%. CONCLUSION: BMI, duration of diabetes, FBG, HbA1c, and visceral fat content are closely associated with the likelihood of achieving dual response to semaglutide regarding glycemic control and weight loss in obese T2DM patients. The nomogram model constructed based on these indicators demonstrates good predictive performance.

Key words: semaglutide, obesity, type 2 diabetes mellitus, glycemic control, weight loss, response

CLC Number: